These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 21673796)

  • 1. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
    Neff CP; Kurisu T; Ndolo T; Fox K; Akkina R
    PLoS One; 2011; 6(6):e20209. PubMed ID: 21673796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
    Neff CP; Ndolo T; Tandon A; Habu Y; Akkina R
    PLoS One; 2010 Dec; 5(12):e15257. PubMed ID: 21203568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.
    Barouch DH; Klasse PJ; Dufour J; Veazey RS; Moore JP
    Proc Natl Acad Sci U S A; 2012 May; 109(22):8694-8. PubMed ID: 22586094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.
    Veselinovic M; Neff CP; Mulder LR; Akkina R
    Virology; 2012 Oct; 432(2):505-10. PubMed ID: 22832125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Semen on Vaginal HIV-1 Transmission and Maraviroc Protection.
    Council OD; Swanson MD; Spagnuolo RA; Wahl A; Garcia JV
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7847-51. PubMed ID: 26392489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.
    Malcolm RK; Veazey RS; Geer L; Lowry D; Fetherston SM; Murphy DJ; Boyd P; Major I; Shattock RJ; Klasse PJ; Doyle LA; Rasmussen KK; Goldman L; Ketas TJ; Moore JP
    Antimicrob Agents Chemother; 2012 May; 56(5):2251-8. PubMed ID: 22330914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV.
    Ball C; Woodrow KA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4855-65. PubMed ID: 24913168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.
    Forbes CJ; McCoy CF; Murphy DJ; Woolfson AD; Moore JP; Evans A; Shattock RJ; Malcolm RK
    J Pharm Sci; 2014 May; 103(5):1422-32. PubMed ID: 24585370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice.
    Berges BK; Akkina SR; Folkvord JM; Connick E; Akkina R
    Virology; 2008 Apr; 373(2):342-51. PubMed ID: 18207484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.
    Forbes CJ; Lowry D; Geer L; Veazey RS; Shattock RJ; Klasse PJ; Mitchnick M; Goldman L; Doyle LA; Muldoon BC; Woolfson AD; Moore JP; Malcolm RK
    J Control Release; 2011 Dec; 156(2):161-9. PubMed ID: 21864598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
    Veselinovic M; Yang KH; LeCureux J; Sykes C; Remling-Mulder L; Kashuba ADM; Akkina R
    Virology; 2014 Sep; 464-465():253-263. PubMed ID: 25105490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.
    Veazey RS; Ketas TJ; Dufour J; Moroney-Rasmussen T; Green LC; Klasse PJ; Moore JP
    J Infect Dis; 2010 Sep; 202(5):739-44. PubMed ID: 20629537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
    Fox J; Tiraboschi JM; Herrera C; Else L; Egan D; Dickinson L; Jackson A; Olejniczak N; Back D; Khoo S; Shattock R; Boffito M
    J Acquir Immune Defic Syndr; 2016 Nov; 73(3):252-257. PubMed ID: 27727157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
    Sepúlveda-Crespo D; Sánchez-Rodríguez J; Serramía MJ; Gómez R; De La Mata FJ; Jiménez JL; Muñoz-Fernández MÁ
    Nanomedicine (Lond); 2015; 10(6):899-914. PubMed ID: 25867856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
    Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
    J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.
    Dezzutti CS; Yandura S; Wang L; Moncla B; Teeple EA; Devlin B; Nuttall J; Brown ER; Rohan LC
    Pharm Res; 2015 Nov; 32(11):3768-81. PubMed ID: 26078001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.
    Kish-Catalone TM; Lu W; Gallo RC; DeVico AL
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1497-509. PubMed ID: 16569870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
    Lieberman-Blum SS; Fung HB; Bandres JC
    Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
    Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
    PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.